Molecure

Name: Molecure
Address: Ulica Żwirki i Wigury 101, Warsaw, 02-089, PL
Telephone: +48225526724

Molecure S.A. to innowacyjna firma biotechnologiczna. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Molecure is a clinical stage biopharmaceutical company that uses its world leading medicinal chemistry capabilities to discover and develop first in class small molecule drug candidates that directly modulate RNA and underexplored protein targets to treat multiple incurable diseases. Molecure has generated a diverse pipeline of nine distinct programs with the support of leading academic life scien

ce institutions globally, including the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science. Molecure’s most advanced in-house compound is OATD-02, an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer that is expected to advance to Phase 1 in the second half of 2022. Molecure has an exclusive collaboration and license agreement with Galapagos for the global development and commercialization of Molecure’s OATD-01. OATD-01 (GLPG4716) is a Phase 2-ready chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases with a fibrotic component. Molecure’s headquarters and laboratories are located in Warsaw, Poland with an additional laboratories in Łódź.

11/02/2026

Happy International Day of Women & Girls in Science! 👩‍🔬

At , we believe science knows no boundaries and neither should opportunities. That’s why we’re proud that 65% of our team are women, driving innovation and passion in biotech every day 💡

On this special day, we celebrate the incredible women and girls shaping the future of science. We are proud to support initiatives that empower women in STEM, such as “Top 100 Women in Biotech in Poland” by Perspektywy Women in Tech 👩‍⚕️

To all the women and girls in science: thank you for your talent, dedication, and inspiration! ✨

03/02/2026

We are pleased to announce the publication dates for Molecure's 2026 reports 📣
➡️ Annual Report for 2025 - March 31, 2026
➡️ Q1 2026 Report - April 30, 2026
➡️ Report for the First Half of 2026 - September 30, 2026
➡️ Q3 2026 Report - October 30, 2026

Stay tuned for updates and insights from as we continue driving innovation in the biotech industry! 🔬

23/12/2025

Wishing you peaceful Holidays, time to recharge and a New Year full of health, growth and exciting opportunities! Thank you for being with us 🎁✨

Merry Christmas from Molecure 🎄

16/12/2025

New interview with ’s CEO now available! 🎙️

Marcin Szumowski talks about how the global biotech recovery is impacting partnering discussions for OATD-01, providing updates on recruitment progress for the Phase II sarcoidosis trial and the possibility of bringing on a strategic partner to support Molecure's long-term strategy and fund further development 🔬

👉 Read the full interview here: https://strefainwestorow.pl/biotechnologia/marcin-szumowski-molecure

09/12/2025

has secured funding from the European Union for the project "Development of a new service for discovering small-molecule compounds with therapeutic potential using artificial intelligence models". The funding agreement No. FENG.01.01-IP.01-A12Q/25 was signed on 9th December 2025. The project will be carried out in consortium with the Institute of Organic Chemistry of the Polish Academy of Sciences.

Project Value: 50 786 076,90 PLN
EU Funds Contribution: 35 727 520,87 PLN

The Project aims to develop an innovative service that enables the identification of compounds with high therapeutic potential, acting through direct interactions with human proteins or mRNA. The service will leverage a proprietary artificial intelligence–based tool used in close conjunction with experimental methods that verify the properties of the generated structures. The project will be commercialized as a new drug-design service offered on international markets, targeted at biopharmaceutical companies, including big pharma, seeking faster, more cost-effective, and more efficient methods for discovering innovative therapies.

More information at: https://molecure.com/pl/molecure-sa-uzyskalo-dotacje-z-unii-europejskiej-na-projekt-opracowanie-nowej-uslugi-odkrywania-zwiazkow-maloczasteczkowych-o-potencjale-terapeutycznym-wykorzystujacej-modele-sztucznej-inteli/ or http://www.mapadotacji.gov.pl/

05/11/2025

Hello from Vienna! 🇦🇹

Our team: Marcin Szumowski (CEO), Zbigniew Zasłona (CSO) and Maurycy Zieliński (Business Development Director), is attending 2025, connecting with biotech and pharma leaders from around the world.

Excited to exchange ideas, explore new partnerships, and showcase Molecure’s commitment to developing first-in-class therapies 🧬

30/10/2025

We’re excited to announce that will be attending 2025 in Vienna, Austria, from November 3-5! 🇦🇹

Representing us on-site will be: Marcin Szumowski - CEO, Zbigniew Zasłona - CSO and Maurycy Zieliński - Business Development Director 🤝

BIO Europe is one of Europe’s leading partnering conferences, bringing together biotech and pharma leaders to foster collaborations and drive innovation 🔬

We’re looking forward to connecting with fellow innovators, exploring new partnership opportunities, and sharing our work in developing first-in-class therapies. See you in Vienna! 👋

20/10/2025

Recently, our team: Katarzyna Aranowska - Clinical Project Manager, Maciej Sawicki - Clinical Trial Administrator, Małgorzata Sobiecka - Quality Assurance Specialist and Małgorzata Borkowska - Project Manager - CMC Clinical Development, had the pleasure of attending the 5th International Conference WE! Are Clinical Research, organized by Kozminski University and Medical University of Warsaw (WUM) ✨

We were especially proud to see our Chief Scientific Officer, Piotr Iwanowski, chair the discussion panel titled “Harmonization of ethical evaluation under the CTR - is it possible?” 💬

It’s inspiring to be part of such an engaged community working together to advance responsible and innovative clinical research 🔬

Adres

Ulica Żwirki I Wigury 101
Warsaw
02-089

Telefon

+48225526724

Strona Internetowa

https://molecure.com/

Ostrzeżenia

Bądź na bieżąco i daj nam wysłać e-mail, gdy Molecure umieści wiadomości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu i możesz zrezygnować z subskrypcji w dowolnym momencie.

Skróty

Chcesz aby twoja firma była na górze listy Firma Inżynieryjna w Warsaw?

Udostępnij

Kategoria

Firma z branży biotechnologii